Ancora Heart today announced it appointed David Tucker as chief financial officer. Tucker will be responsible for the Santa Clara, California-based company's financial strategies and operations as it enrolls patients in the Corcinch-HF pivotal clinical trial of its AccuCinch ventricular restoration system. “David’s experience includes … [Read more...] about Ancora Heart appoints David Tucker as CFO

Ancora Heart today announced it appointed Mark Miles as chief commercial officer. Miles will oversee the Santa Clara, California-based company's commercialization strategy for the AccuCinch ventricular restoration system, a transcatheter procedure to treat enlarged left ventricles in the heart. “Mark’s track record in commercialization and … [Read more...] about Ancora Heart names Mark Miles as chief commercial officer

Ancora Heart announced today that it raised $80 million in equity financing for its AccuCinch ventricular restoration system. Santa Clara, Calif.-based Ancora Heart said in a news release that funds raised in the equity round are earmarked for the acceleration of the Corcinch-HF pivotal clinical study of the AccuCinch system for treating … [Read more...] about Ancora Heart raises $80M for ventricular restoration system

Ancora Heart this week said it has enrolled the first patient in its AccuCinch Ventricular Restoration System pivotal trial. AccuCinch is a flexible implant that is attached to the inner wall of the left ventricle and then cinched. It is designed to reduce the size of the left ventricle, reduce ventricular wall stress and support and strengthen … [Read more...] about Ancora Heart says enrollment has started for AccuCinch pivotal trial